626 reports of this reaction
3.4% of all BETAMETHASONE VALERATE reports
#2 most reported adverse reaction
MACULAR DEGENERATION is the #2 most commonly reported adverse reaction for BETAMETHASONE VALERATE, manufactured by Alembic Pharmaceuticals Inc.. There are 626 FDA adverse event reports linking BETAMETHASONE VALERATE to MACULAR DEGENERATION. This represents approximately 3.4% of all 18,273 adverse event reports for this drug.
Patients taking BETAMETHASONE VALERATE who experience macular degeneration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MACULAR DEGENERATION is moderately reported among BETAMETHASONE VALERATE users, representing a notable but not dominant share of adverse events.
In addition to macular degeneration, the following adverse reactions have been reported for BETAMETHASONE VALERATE:
The following drugs have also been linked to macular degeneration in FDA adverse event reports:
MACULAR DEGENERATION has been reported as an adverse event in 626 FDA reports for BETAMETHASONE VALERATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MACULAR DEGENERATION accounts for approximately 3.4% of all adverse event reports for BETAMETHASONE VALERATE, making it one of the most commonly reported side effect.
If you experience macular degeneration while taking BETAMETHASONE VALERATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.